Phase 1a/1b2026
UBT251: the first-in-human phase 1a/1b study
What did early human testing show about tolerability and drug exposure?
- Participants
- First-in-human cohorts
- Follow-up
- Single exposure / 12 weeks
PRIMARY SOURCES, FRONT AND CENTER
A closer look atthe evidence.
Explore a selection of recent PubMed records for tracked compounds. Search titles, filter publication types, and read each study at its source.
Connected to PubMed
RECENT PAPERS / PUBMED
Follow the latest questions.
A live literature feed. Publication dates and study types come from the source records.
Fetching all studies from PubMed…
Recent papers for tracked compounds. Each publication-type filter retrieves its own selection from PubMed. Labels come from PubMed publication types; they do not rate evidence quality.
Research starts with a question.
Explore metabolism, recovery, sleep and more, with study context beside each compound.
Browse research by goal →AN EMERGING MOLECULE TO FOLLOWUBT251 · triple agonist
Three targets. A new set of questions.
Early human studies are exploring UBT251’s effects on weight and blood glucose. Get the 24-week results, understand the receptor-balance discussion, and see which trials come next.
STUDIES WORTH UNDERSTANDING
How to read a studyBeyond the headline.
Selected studies and clinical reports, with the question, context and limitations close at hand.
Conference abstract2026
UBT251: the 24-week phase 2 obesity results
Which trial arm produced the 19.7% weight-loss headline?
- Participants
- 205 Chinese adults
- Follow-up
- 24 weeks
Preclinical2011
BPC-157: tendon outgrowth and cell migration
What cellular changes might help explain the interest in tendon research?
- Participants
- Rat tendon explants and cells
- Follow-up
- Laboratory assays
Retrospective report2021
BPC-157: a small retrospective knee-pain report
What did a small practice report about pain after joint injections?
- Participants
- 17 charts; 16 followed up
- Follow-up
- Variable; mostly 6–12 months
Safety pilot2025
BPC-157: what a two-person IV pilot can tell us
What was observed during a very small, short-term intravenous pilot?
- Participants
- 2 adults
- Follow-up
- 3 days of observation
Phase 32007
Tesamorelin: the pivotal visceral-fat trial
Could stimulating GH release reduce visceral abdominal fat in adults with HIV?
- Participants
- 412 adults
- Follow-up
- 26 weeks
Explore all 18 study summaries
Randomized trial2014
Tesamorelin: visceral and liver fat
Did tesamorelin affect fat in the liver as well as around internal organs?
- Participants
- 50 randomized adults
- Follow-up
- 6 months
Phase 22017
Tesamorelin: what the 1 mg / 2 mg trial tested
What did a direct comparison of 1 mg, 2 mg and placebo actually measure?
- Participants
- 53 adults in the published report
- Follow-up
- 12 weeks
Randomized trial2019
Tesamorelin: liver fat in HIV-associated NAFLD
Could tesamorelin reduce liver fat in people with HIV and fatty liver disease?
- Participants
- 61 enrolled; 60 received treatment
- Follow-up
- 12-month randomized phase
Phase 32026
Retatrutide: TRIUMPH-1 phase 3
Could retatrutide improve weight and obesity-related outcomes in a larger trial?
- Participants
- 2,339 adults
- Follow-up
- 80 weeks
Phase 32026
Retatrutide: TRIUMPH-2 phase 3
What happened in people with both obesity and type 2 diabetes?
- Participants
- 1,152 adults
- Follow-up
- 80 weeks
Phase 22023
Retatrutide: the phase 2 obesity trial
Could a peptide acting on GIP, GLP-1, and glucagon receptors reduce body weight in adults with obesity?
- Participants
- 338 adults
- Follow-up
- 48 weeks
Phase 22023
Retatrutide: glucose and weight in type 2 diabetes
Could triple-receptor activity improve glucose regulation as well as body weight?
- Participants
- 281 adults
- Follow-up
- 36 weeks
Phase 2a substudy2024
Retatrutide: a closer look at liver fat
Did liver fat change in participants with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD)?
- Participants
- 98 adults
- Follow-up
- 24-week primary assessment; 48-week study
Phase 2 substudy2025
Retatrutide: fat loss and lean mass
What did DXA scans show about the body composition behind the weight change?
- Participants
- 189 enrolled in substudy
- Follow-up
- 36 weeks
Phase 32022
Tirzepatide: SURMOUNT-1
How did tirzepatide compare with placebo for weight reduction in adults with obesity or overweight and a weight-related complication?
- Participants
- 2,539 adults
- Follow-up
- 72 weeks
Phase 32021
Semaglutide: STEP 1
What happened when semaglutide was added to lifestyle intervention in adults with obesity or overweight?
- Participants
- 1,961 adults
- Follow-up
- 68 weeks
Outcomes trial2023
Semaglutide: SELECT cardiovascular outcomes
Could semaglutide reduce major cardiovascular events in people with established cardiovascular disease and overweight or obesity, without diabetes?
- Participants
- 17,604 adults
- Follow-up
- 39.8 months mean follow-up
KEEP EXPLORING
Go straight to the source.
Use papers, full texts, and trial records to answer different research questions.
01 / LITERATURE
Europe PMC ↗
Search life-science literature and linked full texts. Check whether a record is a published paper or a preprint.
02 / FULL TEXTPubMed Central ↗
Read available full papers, including methods, tables, and limitations that an abstract may leave out.
03 / TRIAL RECORDSClinicalTrials.gov ↗
Check registered study designs, eligibility, endpoints, and posted results. Registration does not itself establish effectiveness.
Who or what was studied? What was measured? A title is a starting point. Open the original paper to understand its methods, results, and limitations.
A guide to reading studies →How this feed works →